Evidence map›Paper›PMID 38359926›Full record

Observational studyThorax2024

Indirect impact of childhood 13-valent pneumococcal conjugate vaccine (PCV13) in Canadian older adults: a Canadian Immunization Research Network (CIRN) retrospective observational study.

Sharifa Nasreen, Jun Wang, Fawziah Marra, Jeffrey C Kwong, Allison McGeer, Manish Sadarangani, Sarah E Wilson, Shaza A Fadel

Open access · hybridAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Thorax, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.8field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 2 countries.

Sharifa NasreenUniversity of Toronto Dalla Lana School of Public Health, Toronto, Ontario, Canada.ORCID 0000-0002-9793-113X
Jun WangICES, Toronto, Ontario, Canada.
Fawziah MarraFaculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, British Columbia, Canada.
Jeffrey C KwongUniversity of Toronto Dalla Lana School of Public Health, Toronto, Ontario, Canada.
Allison McGeerUniversity of Toronto Dalla Lana School of Public Health, Toronto, Ontario, Canada.
Manish SadaranganiDepartment of Pediatrics, University of British Columbia Faculty of Medicine, Vancouver, British Columbia, Canada.
Sarah E WilsonUniversity of Toronto Dalla Lana School of Public Health, Toronto, Ontario, Canada.
Shaza A FadelUniversity of Toronto Dalla Lana School of Public Health, Toronto, Ontario, Canada shaza.fadel@utoronto.ca.ORCID 0000-0002-2336-6254
University of Toronto · CAUniversity of British Columbia · CAPublic Health Ontario · CASUNY Downstate Health Sciences University · USUniversity Health Network · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

background13-valent pneumococcal conjugate vaccine (PCV13) has been part of publicly funded childhood immunisation programmes in Ontario and British Columbia (BC) since 2010. We assessed the indirect impact of infant PCV13 programmes on invasive pneumococcal disease (IPD) and all-cause pneumonia hospitalisation in older adults (aged ≥65 years) using a retrospective observational study.

methodsWe extracted monthly IPD and all-cause pneumonia cases from laboratory and health administrative databases between January 2005 and December 2018. Using a quasi-experimental difference-in-differences design, we calculated the ratio of risk ratios (RRRs) using incidence rates of IPD or all-cause pneumonia cases before (pre-PCV13 period) and after (PCV13 period) 2010 with rates of fractures as controls.

resultsThe rates of all IPD or PCV serotype-specific IPD for older adults in both Ontario and BC did not change in 8 years after childhood PCV13 programme implementation. All-cause pneumonia increased in Ontario (RRR 1.38, 95% CI 1.11 to 1.71) but remained unchanged in BC.

conclusionsIndirect community protection of older adults from hospitalisation with pneumococcal disease stalled despite maturation of childhood PCV13 vaccination programmes in two Canadian provinces.

Indexed as

HospitalizationPneumococcal InfectionsPneumococcal VaccinesAgedAged, 80 and overBritish ColumbiaFemaleHumansImmunization ProgramsIncidenceMaleOntarioPneumonia, PneumococcalRetrospective StudiesVaccines, Conjugate13-valent pneumococcal vaccinePneumococcal VaccinesVaccines, ConjugateBacterial InfectionPneumoniaRespiratory Infection

Identifiers

PMID38359926
PMCPMC11347212
OpenAlexW4391845332

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.